OMass Therapeutics

📍 Oxford, United Kingdom🗓 Founded 2016👥 80 employees💰 Last funded Apr 2023
Biotechnology Research🌐 omass.com
Website LinkedIn
OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
2
Frequently asked questions
Who invested in OMass Therapeutics?
OMass Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did OMass Therapeutics last raise funding?
The most recent investment in OMass Therapeutics recorded on gritt.io was in April 2023.
When was OMass Therapeutics founded?
OMass Therapeutics was founded in 2016.
What industry is OMass Therapeutics in?
OMass Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is OMass Therapeutics based?
OMass Therapeutics is headquartered in Oxford, United Kingdom.